|
May 10
|
Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ...
|
|
May 10
|
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
|
|
May 9
|
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 9
|
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
|
|
Apr 23
|
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
|
|
Apr 11
|
Century buys a startup, raises funding in cell therapy expansion
|
|
Apr 11
|
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
|
|
Apr 8
|
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
|
|
Mar 29
|
Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely
|
|
Mar 25
|
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
|
|
Mar 20
|
Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar?
|
|
Mar 19
|
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
|
|
Mar 14
|
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
|
|
Mar 9
|
Century Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 Shares
|
|
Mar 7
|
How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4%
|
|
Mar 5
|
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
|
|
Dec 9
|
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
|
|
Dec 7
|
Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study
|
|
Dec 7
|
Century Therapeutics, Inc.'s (NASDAQ:IPSC) largest shareholders are public companies who were rewarded as market cap surged US$47m last week
|
|
Dec 6
|
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
|